Sean W Ong

List of Publications by Year
in descending order

44 papers	13,290 citations	361413 20 h-index	276875 41 g-index
50 all docs	50 docs citations	50 times ranked	26863 citing authors

#	Article	IF	Citations
1	Viral Load of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Respiratory Aerosols Emitted by Patients With Coronavirus Disease 2019 (COVID-19) While Breathing, Talking, and Singing. Clinical Infectious Diseases, 2022, 74, 1722-1728.	5.8	143
2	Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clinical Infectious Diseases, 2022, 75, e1128-e1136.	5.8	323
3	Accuracy of a Rapid Multiplex Polymerase Chain Reaction Plus a Chromogenic Phenotypic Test Algorithm for Detection of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Gram-Negative Bacilli in Positive Blood Culture Bottles. Clinical Infectious Diseases, 2022, 74, 1850-1854.	5.8	1
4	Transmission modes of severe acute respiratory syndrome coronavirus 2 and implications for infection control: a review. Singapore Medical Journal, 2022, 63, 61-67.	0.6	13
5	Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clinical Microbiology and Infection, 2022, 28, 612.e1-612.e7.	6.0	231
6	Antibiotic Therapy in the Treatment of COVID-19 Pneumonia: Who and When?. Antibiotics, 2022, 11, 184.	3.7	9
7	Validation of ISARIC 4C Mortality and Deterioration Scores in a Mixed Vaccination Status Cohort of Hospitalized Coronavirus Disease 2019 (COVID-19) Patients in Singapore. Clinical Infectious Diseases, 2022, 75, e874-e877.	5.8	6
8	External validation of the PRIORITY model in predicting COVID-19 critical illness in vaccinated and unvaccinated patients. Clinical Microbiology and Infection, 2022, 28, 884.e1-884.e3.	6.0	4
9	Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study. Antibiotics, 2022, 11, 345.	3.7	15
10	SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond. Expert Review of Respiratory Medicine, 2022, 16, 499-502.	2.5	10
11	PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer—A Prospective Study of Men with 3 Year Follow Up. Cancers, 2022, 14, 2717.	3.7	6
12	Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. Clinical Infectious Diseases, 2021, 73, e2932-e2942.	5.8	143
13	Vaccine-associated Rubella – a report of two cases and a review of the literature. Human Vaccines and Immunotherapeutics, 2021, 17, 224-227.	3.3	6
14	Environmental contamination in a coronavirus disease 2019 (COVID-19) intensive care unit—What is the risk?. Infection Control and Hospital Epidemiology, 2021, 42, 669-677.	1.8	33
15	Lack of viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among PCR-positive air samples from hospital rooms and community isolation facilities. Infection Control and Hospital Epidemiology, 2021, 42, 1327-1332.	1.8	26
16	Haemophagocytic lymphohistiocytosis in dengue fever. Lancet Infectious Diseases, The, 2021, 21, 437.	9.1	1
17	Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. Open Forum Infectious Diseases, 2021, 8, ofab156.	0.9	77
18	Predictors for development of critical illness amongst older adults with COVID-19: Beyond age to age-associated factors. Archives of Gerontology and Geriatrics, 2021, 94, 104331.	3.0	27

#	Article	IF	Citations
19	Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe, The, 2021, 2, e240-e249.	7.3	322
20	Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes. Lancet Infectious Diseases, The, 2021, 21, 1195-1197.	9.1	29
21	High-risk chest radiographic features associated with COVID-19 disease severity. PLoS ONE, 2021, 16, e0245518.	2.5	9
22	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 1365-1376.	10.7	119
23	Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals. Frontiers in Immunology, 2021, 12, 710217.	4.8	8
24	Global surveillance, research, and collaboration needed to improve understanding and management of long COVID. Lancet, The, 2021, 398, 2057-2059.	13.7	19
25	The Pandemic Academy: Reflections of Infectious Diseases Fellows During COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa256.	0.9	3
26	Safety and potential efficacy of cyclooxygenase‑2 inhibitors in coronavirus disease 2019. Clinical and Translational Immunology, 2020, 9, e1159.	3.8	19
27	Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) infection. Clinical and Translational Immunology, 2020, 9, e1160.	3.8	31
28	The Effect of Sample Site, Illness Duration, and the Presence of Pneumonia on the Detection of SARS-CoV-2 by Real-time Reverse Transcription PCR. Open Forum Infectious Diseases, 2020, 7, ofaa335.	0.9	19
29	Outbreak of Measles in a Residential Home for the Intellectually Disabled in Singapore in 2019. American Journal of Public Health, 2020, 110, 1532-1534.	2.7	0
30	Neurocysticercosis Diagnosed by Taenia solium PCR on Brain Biopsy. Case Reports in Infectious Diseases, 2020, 2020, 1-4.	0.5	1
31	Association of Higher Body Mass Index With Severe Coronavirus Disease 2019 (COVID-19) in Younger Patients. Clinical Infectious Diseases, 2020, 71, 2300-2302.	5.8	51
32	Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. Nature Communications, 2020, 11, 2800.	12.8	703
33	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. New England Journal of Medicine, 2020, 383, 1827-1837.	27.0	1,152
34	Epidemiological and Clinical Predictors of COVID-19. Clinical Infectious Diseases, 2020, 71, 786-792.	5.8	181
35	Absence of contamination of personal protective equipment (PPE) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection Control and Hospital Epidemiology, 2020, 41, 614-616.	1.8	59
36	Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. JAMA - Journal of the American Medical Association, 2020, 323, 1610.	7.4	1,742

#	ARTICLE	IF	CITATIONS
37	Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA - Journal of the American Medical Association, 2020, 323, 1488.	7.4	1,700
38	Severe dengue and liver involvement: an overview and review of the literature. Expert Review of Anti-Infective Therapy, 2020, 18, 181-189.	4.4	17
39	Remdesivir for the Treatment of Covid-19 â€" Final Report. New England Journal of Medicine, 2020, 383, 1813-1826.	27.0	5,834
40	Singapore Medical Journal in the age of social media. Singapore Medical Journal, 2020, 61, 501-502.	0.6	3
41	Characterisation of bone and joint infections due to Group B Streptococcus serotype III sequence type 283. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1313-1317.	2.9	4
42	Incidence of Carpal Coalition in an Asian Population â€" Preliminary Findings of a Study on Patients from a Distal Radius Fracture Database. journal of hand surgery Asian-Pacific volume, The, 2017, 22, 156-159.	0.4	1
43	Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. , 0, .		1
44	Genomic surveillance uncovers ongoing transmission of carbapenem-resistant *Acinetobacter baumannii* (CRAB) and identifies actionable routes of transmissions in an endemic setting. Infection Control and Hospital Epidemiology, 0, , 1-7.	1.8	0